All In Biotech

Drug Trial Radar · NCT07227870

L19IL2/TNF in Patients With Basal Cell Carcinoma

A Phase 2 Study of Intratumoral Administration of L19IL2/L19TNF in Locally Advanced Basal Cell Carcinoma Patients Progressing or Intolerant to Systemic Treatment.

Last checked: Nov 19, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

92

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Feb 2031

Study completion Feb 2031

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Nov 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, single-arm, multicentre study in patients with locally advanced BCC amenable to intratumoral injection, who have progressed on or are intolerant to systemic therapy as determined by a local multidisciplinary tumor board. The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four weekly injections may be administered as per treating physician judgement. Patients will be followed for a maximum of 160 weeks after beginning of treatment.

Conditions

  • Locally Advanced Basal Cell Carcinoma

Interventions

  • L19IL2/L19TNFDrug

    intratumoral administrations

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Best Overall Response Rate (BORR)Time frame: From enrollment up to a maximum of 160 weeks after the start of treatment

Locations

18 sites in 5 countries. Site status is shown where the registry gives one.

  • H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc.

    Tampa, Florida · Recruiting

  • Winship Cancer Institute, Emory University

    Atlanta, Georgia · Recruiting

  • Memorial Sloan Kettering

    New York, New York · Not yet recruiting

  • The Ohio State University Wexner Medical Center Clinical Laboratories

    Columbus, Ohio · Not yet recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Universitaetsklinikum Augsburg

    Augsburg, Germany · Recruiting

  • Charite Universitaetsmedizin Berlin KöR

    Berlin, Germany · Recruiting

  • Universitaetsklinikum Essen AöR

    Essen, Germany · Recruiting

  • Universitaetsklinikum Halle (Saale) AöR

    Halle, Germany · Recruiting

  • Heidelberg University

    Heidelberg, Germany · Recruiting

  • Universitaetsklinikum Schleswig-Holstein AöR

    Kiel, Germany · Recruiting

  • Universitaetsklinikum Tuebingen AöR

    Tübingen, Germany · Recruiting

  • Andreas Syngros Hospital Of Venereal And Dermatological Diseases

    Athens, Greece · Not yet recruiting

  • IRCCS Istituto Nazionale Tumori Fondazione Pascale

    Naples, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy · Recruiting

  • Humanitas Mirasole S.p.A.

    Rozzano, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria Senese

    Siena, Italy · Recruiting

  • Hospital Clinic De Barcelona

    Barcelona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.